Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer

Completed · Phase 4 · Has a placebo group

Conditions studied: Prostate Cancer

In brief

Men treated with neoadjuvant luteinizing hormone-releasing hormone (LHRH)-agonists such as leuprolide and goserelin for prostate cancer will become hypogonadal due to hormonal suppression and demonstrate increased bone turnover and consequent bone loss at the hip and spine. This bone loss can be prevented by treatment with 35 mg/week of risedronate.

Key facts

Study ID

NCT00859027

Run by

UConn Health

People needed

50

Starts

2003-01-01

Expected to finish

2009-02-01

Last updated by the study team

2018-05-01

Who can join

Age: 55 and older, up to 85. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Non-metastatic prostate cancer
• Men to receive Gonadotropin-releasing Hormone-agonist therapy

You may not qualify if…

• Other cancers except skin cancer
• Evidence of metabolic bone disease
• Prior use of bisphosphonates

Where it is running

• University of Connecticut Health Center — Farmington, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.